Table 1 General characteristics of the reviewed studies and the primary results
Age (years)b | CD4+ counts (cells/μL)c | Assay resultse | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Investigators | Year | Country | ATB/non-ATB patients enrolleda | ATB patients | Non-ATB patients | ATB patients | Non-ATB patients | IGRA methodd | TP | FP | FN | TN | I |
Aichelburg | 2009 | Austria | 8/822 | 39 (32–47) | 39 (32–47) | 393 (264–566) | 393 (264–566) | QFT-IT | 7 | 37 | 1 | 738 | 47 |
Davarpanah | 2009 | Iran | 11/165 | 38 (23–60) | 38 (23–60) | 360 (34–1300) | 360 (34–1300) | QFT-IT | 4 | 45 | 7 | 107 | 13 |
Veldsman | 2009 | South Africa | 30/30 | NR | NR | NR | NR | QFT-IT | 9 | 11 | 15 | 16 | 9 |
Cattamanchi | 2010 | Uganda | 112/100 | 33 (27–40) | 33 (27–40) | 49 (16–160) | 49 (16–160) | T-SPOT | 61 | 34 | 23 | 40 | 54 |
Legesse | 2010 | Ethiopia | 6/21 | 34.2 (18–70) | 34.2 (18–70) | NR | NR | QFT-IT | 5 | 10 | 1 | 10 | 1 |
Leidl | 2010 | Uganda | 19/109 | 33.4 ± 6 | 34.1 ± 8.3 | 182 (118) | 283 (226) | T-SPOT | 17 | 59 | 0 | 46 | 6 |
QFT-IT | 13 | 74 | 6 | 31 | 4 | ||||||||
Tan | 2010 | Taiwan | 9/30 | 39.6 (30–52) | 39.1 (19–67) | 112 (31–332) | 145 (0–596) | T-SPOT | 8 | 2 | 1 | 28 | 0 |
Bua | 2011 | Italy | 9/64 | 41 (21–63) | 41 (21–63) | 270 (4–897) | 270 (4–897) | QFT-IT | 2 | 6 | 6 | 47 | 12 |
Rangaka | 2011 | South Africa | 50/729 | 35 (31–40) | 36 (31–42) | 169 (98–239) | 198 (136–315) | QFT-IT | 32 | 298 | 15 | 383 | 51 |
Lagrange | 2013 | India | 38/54 | 38.0 (30.5-42.0) | 38.0 (30.5-42.0) | NR | NR | QFT-IT | 26 | 19 | 3 | 29 | 15 |
Markova | 2014 | Bulgaria | 13/52 | 43 (29 – 63) | 37 (21–66) | 195 (15–450) | 248 (36–785) | T-SPOT | 8 | 0 | 1 | 48 | 8 |
QFT-IT | 12 | 0 | 1 | 49 | 3 | ||||||||